Home / Market News / $VCYT

$VCYT news and market catalysts

The 6 most recent market catalysts affecting $VCYT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

6 catalysts 0 high impact 3 bullish 2 bearish Biotechnology
Sep 9, 2026 Market Technicals Bullish Impact 55
UBS Maintains Buy on Veracyte, Raises Price Target to $65
UBS analyst Doug Schenkel has maintained a 'Buy' rating on Veracyte and raised the price target from $52 to $65. This upgrade signals increased confidence from a major financial in…
Aug 19, 2026 Market Technicals Bearish Impact 55
Top 3 Health Care Stocks That Could Blast Off This Month
The filing identifies Veracyte Inc (VCYT), Akso Health Group (AHG), and Inogen Inc (INGN) as oversold healthcare stocks, each with an RSI below 30. This technical indicator suggest…
Aug 4, 2026 Corporate Catalyst Bearish Impact 55
Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $44
Morgan Stanley analyst Tejas Savant maintained an 'Underweight' rating on Veracyte and lowered the price target from $47 to $44. This action indicates a continued bearish sentiment…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
Needham Maintains Buy on Veracyte, Raises Price Target to $69
Needham analyst Mike Matson maintained a 'Buy' rating on Veracyte and raised the price target from $57 to $69. This action signals increased confidence from a prominent analyst in …
Jul 30, 2026 Corporate Catalyst Bullish Impact 75
Veracyte Raises FY2026 Sales Guidance from $582.000M-$592.000M to $590.000M-$596.000M vs $586.445M Est
Veracyte (VCYT) announced an upward revision to its fiscal year 2026 sales guidance, moving from a range of $582.000 million-$592.000 million to $590.000 million-$596.000 million. …
Jul 15, 2026 Corporate Catalyst Neutral Impact 65
Piper Sandler Initiates Coverage On Veracyte with Overweight Rating, Announces Price Target of $66
Piper Sandler analyst David Westenberg has initiated coverage on Veracyte (VCYT) with an Overweight rating and a $66 price target. This is a significant event for VCYT as new analy…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.